

FOR IMMEDIATE RELEASE

Contact:

Jon Boroshok, Public Relations

978-502-1055

jonb@hairdx.com

[Twitter: @HairDX](https://twitter.com/HairDX)

Dermatology Study Identifies Genetic Key In Treatment Of Female Hair Loss

HairDX Announces Pilot Study Results

IRVINE, CA, FEBRUARY 23, 2010 - [Molecular dermatology research and development innovator HairDX](#) today announced the results of a six month pilot study that presents, for the first time, evidence that genetic mechanisms may predict treatment response to Finasteride for postmenopausal female Androgenetic Alopecia (female hair loss).

“While Finasteride therapy in men has proven very effective in treating Androgenetic Alopecia (male pattern baldness), there have been frustratingly few therapies for the treatment of hair loss in women. Results of our pilot study are very encouraging, as it appears we have found a key piece of the genetic puzzle which identifies women who can benefit from Finasteride therapy in the same way men do. Our findings suggest these women actually have a female corollary to male pattern hair loss (Androgenetic Alopecia), and that is an important finding,” says Dr. Sharon Keene, Chief Medical Officer of HairDX. “Once these results are confirmed, it can usher in a new era of treatment for female Androgenetic Alopecia.”

“The double-blinded placebo study followed a small cohort of postmenopausal female patients suffering from Androgenetic Alopecia for a period of six months. Using a genetic technique patented by HairDX, we were able to identify women that [benefited from Finasteride](#) by experiencing a significant increase in hair counts,” says Andy Goren, Chief Executive Officer.

About HairDX, LLC.

HairDX (www.hairdx.com and [Twitter: @HairDX](https://twitter.com/HairDX)) is a molecular dermatology company founded in 2007 by leading researchers and specialists in genetics and dermatology. It is dedicated to the research and development of new prescription based therapies for skin conditions tailored to an individual's genetic makeup.

The company introduced HairDX, a [genetic screening test for Female](#) and [Male Pattern Baldness](#) (Androgenetic Alopecia). The HairDX sample collection kit is listed with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) and the United States Food and Drug Administration (FDA) as a Class I medical device.

[The HairDX Genetic Test for Hair Loss](#) is also available as a CE Marked product under the European In Vitro Diagnostic Directive.

#